Teva shares soar on olanzapine efficacy in schizophrenia

Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) and France-based Medincell (Euronext: MEDCL) have announced results from the efficacy portion of the Phase III SOLARIS trial of olanzapine once-monthly long-acting injectable in schizophrenia compared to placebo.

This drug candidate - also referred to as TEV-‘749 - uses SteadyTeq, a copolymer technology proprietary to Medincell that provides a controlled steady release of olanzapine, the most prescribed second generation antipsychotic for schizophrenia in the USA.

"An effective long-acting treatment option for schizophrenia"The study met its primary endpoint, demonstrating a well-tolerated effective long-acting treatment option for schizophrenia, with no incidence of post-injection delirium/sedation syndrome observed to date.